人诱导多能干细胞衍生的心肌细胞：心血管药理学中的新主力？ - Suppr | 超能文献

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?

作者信息

Lemoine Marc D, Christ Torsten

机构信息

Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany; and.

出版信息

J Cardiovasc Pharmacol. 2021 Mar 1;77(3):265-266. doi: 10.1097/FJC.0000000000000981.

DOI:10.1097/FJC.0000000000000981

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?人诱导多能干细胞衍生的心肌细胞：心血管药理学中的新主力？

J Cardiovasc Pharmacol. 2021 Mar 1;77(3):265-266. doi: 10.1097/FJC.0000000000000981.

2

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.诱导多能干细胞在心脏疾病建模和药物测试中的应用。

J Cardiovasc Transl Res. 2018 Oct;11(5):366-374. doi: 10.1007/s12265-018-9811-3. Epub 2018 May 29.

3

Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.源自人类多能干细胞的心肌细胞：从实验室的新奇事物到工业生物医学平台。

Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1728-48. doi: 10.1016/j.bbamcr.2015.10.014. Epub 2015 Oct 31.

4

High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.用于药物开发的诱导多能干细胞衍生心肌细胞的高通量生理筛选。

Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1717-27. doi: 10.1016/j.bbamcr.2016.03.003. Epub 2016 Mar 4.

5

Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.基于多能干细胞的平台在心脏病建模和药物测试中的应用

Clin Pharmacol Ther. 2017 Aug;102(2):203-208. doi: 10.1002/cpt.722.

6

High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.通过动力学图像细胞术高通量测量人干细胞衍生心肌细胞中的Ca++动态变化：使用大量具有心脏活性和无活性化合物进行心脏风险评估特征分析

Toxicol Sci. 2015 Dec;148(2):503-16. doi: 10.1093/toxsci/kfv201. Epub 2015 Sep 9.

7

Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.在人诱导多能干细胞衍生的心肌细胞中进行的结构和功能筛选能够准确识别多种药物类型的心脏毒性。

Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60. doi: 10.1016/j.taap.2015.03.008. Epub 2015 Apr 2.

8

In vitro uses of human pluripotent stem cell-derived cardiomyocytes.人多能干细胞衍生心肌细胞的体外应用。

J Cardiovasc Transl Res. 2012 Oct;5(5):581-92. doi: 10.1007/s12265-012-9376-5. Epub 2012 May 26.

9

A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.一项在人干细胞衍生心肌细胞中进行的多参数体外筛选鉴定出了波纳替尼诱导的心脏结构和功能毒性。

Toxicol Sci. 2015 Jan;143(1):147-55. doi: 10.1093/toxsci/kfu215. Epub 2014 Oct 10.

10

Induced pluripotent stem cells in cardiovascular drug discovery.诱导多能干细胞在心血管药物研发中的应用。

Circ Res. 2013 Feb 1;112(3):534-48. doi: 10.1161/CIRCRESAHA.111.250266.

引用本文的文献

1

Human induced pluripotent stem cell-derived cardiomyocytes as an electrophysiological model: Opportunities and challenges-The Hamburg perspective.人诱导多能干细胞衍生的心肌细胞作为一种电生理模型：机遇与挑战——汉堡视角

Front Physiol. 2023 Feb 16;14:1132165. doi: 10.3389/fphys.2023.1132165. eCollection 2023.